Role of Scaffold Protein Proline-, Glutamic Acid-, and Leucine-Rich Protein 1 (PELP1) in the Modulation of Adrenocortical Cancer Cell Growth

PELP1 acts as an estrogen receptor (ER) coactivator that exerts an essential role in the ER's functions. ER coregulators have a critical role in the progression and response to hormonal treatment of estrogen-dependent tumors. We previously demonstrated that, in adrenocortical carcinoma (ACC), ER\u3b1 is upregulated and that estradiol activates the IGF-II/IGF1R signaling pathways defining the role of this functional cross-talk in H295R ACC cell proliferation. The aim of this study was to determine if PELP1 is expressed in ACC and may play a role in promoting the interaction between ER\u3b1 and IGF1R allowing the activation of pathways important for ACC cell growth. The expression of PELP1 was detected by Western blot analysis in ACC tissues and in H295R cells. H295R cell proliferation decrease was assessed by A3-(4,5-Dimethylthiaoly)-2,5-diphenyltetrazolium bromide (MTT) assay and [3H] thymidine incorporation. PELP1 is expressed in ACC tissues and in H295R cells. Moreover, treatment of H295R with E2 or IGF-II induced a multiprotein complex formation consisting of PELP1, IGF1R, ER\u3b1, and Src that is involved in ERK1/2 rapid activation. PELP1/ER/IGF1R/c-Src complex identification as part of E2- and IGF-II-dependent signaling in ACC suggests PELP1 is a novel and more efficient potential target to reduce ACC growth

GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo

We have previously demonstrated that estrogen receptor (ER) alpha (ESR1) increases proliferation of adrenocortical carcinoma (ACC) through both an estrogen-dependent and -independent (induced by IGF-II/IGF1R pathways) manner. Then, the use of tamoxifen, a selective estrogen receptor modulator (SERM), appears effective in reducing ACC growth in vitro and in vivo. However, tamoxifen not only exerts antiestrogenic activity, but also acts as full agonist on the G protein-coupled estrogen receptor (GPER). Aim of this study was to investigate the effect of a non-steroidal GPER agonist G-1 in modulating ACC cell growth. We found that G-1 is able to exert a growth inhibitory effect on H295R cells both in vitro and, as xenograft model, in vivo. Treatment of H295R cells with G-1 induced cell cycle arrest, DNA damage and cell death by the activation of the intrinsic apoptotic mechanism. These events required sustained extracellular regulated kinase (ERK) 1/2 activation. Silencing of GPER by a specific shRNA partially reversed G-1-mediated cell growth inhibition without affecting ERK activation. These data suggest the existence of G-1 activated but GPER-independent effects that remain to be clarified. In conclusion, this study provides a rational to further study G-1 mechanism of action in order to include this drug as a treatment option to the limited therapy of ACC

Antioxidant, enzyme-inhibitory and antitumor activity of the wild dietary plant Muscari comosum (L.) Mill.

Conventional medicines used to treat obesity and cancer frequently exhibit high side effects, so that researchers are focusing on new therapies and drugs based on natural products. Total extracts from bulbs of Muscari comosum were tested for i) free radical scavenging activity, ii) in vitro enzymatic inhibition of pancreatic α-amylase and lipase, and iii) inhibition of the growth of breast adenocarcinoma cells. Three treatments were considered: bulbs boiled in water for 15 min (traditional cooking method; BB); bulbs steam-cooked for 15 min (alternative cooking method; SB); raw bulbs (RB). The polyphenol content and antioxidant capacity of bulb extracts were related to the inhibition of pancreatic lipase and α-amylase, whose activities have been found to have a half maximal inhibitory concentration (IC50) of 0.28, 2.14 and 3.22 mg/mL for lipase, and 0.16, 0.73 and 0.69 mg/mL for α-amylase in RB, SB and BB, respectively. The analysis on breast adenocarcinoma MCF-7 cells revealed that RB extracts, and in a lesser extent BB, exerted a dose-dependent inhibition on cell proliferation. Considering that the potential of natural products for the treatment of obesity are under exploration, M. comosum could be an excellent plant for the development of future anti-obesity drugs, also able to prevent cancer

Estrogen Related Receptor Alpha (ERRα) a Bridge between Metabolism and Adrenocortical Cancer Progression

The aim of this study was to investigate the metabolic changes that occur in adrenocortical cancer (ACC) cells in response to the modulation of Estrogen Related Receptor (ERR)α expression and the impact on ACC progression. Proteomics analysis and metabolic profiling highlighted an important role for ERRα in the regulation of ACC metabolism. Stable ERRα overexpression in H295R cells promoted a better mitochondrial fitness and prompted toward a more aggressive phenotype characterized by higher Vimentin expression, enhanced cell migration and spheroids formation. By contrast, a decrease in ERRα protein levels, by molecular (short hairpin RNA) and pharmacological (inverse agonist XCT790) approaches modified the energetic status toward a low energy profile and reduced Vimentin expression and ability to form spheroids. XCT790 produced similar effects on two additional ACC cell lines, SW13 and mitotane-resistant MUC-1 cells. Our findings show that ERRα is able to modulate the metabolic profile of ACC cells, and its inhibition can strongly prevent the growth of mitotane-resistant ACC cells and the progression of ACC cell models to a highly migratory phenotype. Consequently, ERRα can be considered an important target for the design of new therapeutic strategies to fight ACC progression

Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment

Cholesterol is essential for cell function and viability. It is a component of the plasma membrane and lipid rafts and is a precursor for bile acids, steroid hormones, and Vitamin D. As a ligand for estrogen-related receptor alpha (ESRRA), cholesterol becomes a signaling molecule. Furthermore, cholesterol-derived oxysterols activate liver X receptors (LXRs) or estrogen receptors (ERs). Several studies performed in cancer cells reveal that cholesterol synthesis is enhanced compared to normal cells. Additionally, high serum cholesterol levels are associated with increased risk for many cancers, but thus far, clinical trials with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have had mixed results. Statins inhibit cholesterol synthesis within cells through the inhibition of HMG-CoA reductase, the rate-limiting enzyme in the mevalonate and cholesterol synthetic pathway. Many downstream products of mevalonate have a role in cell proliferation, since they are required for maintenance of membrane integrity; signaling, as some proteins to be active must undergo prenylation; protein synthesis, as isopentenyladenine is an essential substrate for the modification of certain tRNAs; and cell-cycle progression. In this review starting from recent acquired findings on the role that cholesterol and its metabolites fulfill in the contest of cancer cells, we discuss the results of studies focused to investigate the use of statins in order to prevent cancer growth and metastasis

Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment

The estrogen-related receptors (ERRs) are important members of nuclear receptors which contain three isoforms (α, β, and γ). ERRα is the best-characterized isoform expressed mainly in high-energy demanding tissues where it preferentially works in association with the peroxisome proliferator-activated receptor-γ co-activator 1α (PGC-1α) and PGC-1β. ERRα together with its cofactors modulates cellular metabolism, supports the growth of rapidly dividing cells, directs metabolic programs required for cell differentiation and maintains cellular energy homeostasis in differentiated cells. In cancer cells, the functional association between ERRα and PGC-1s is further influenced by oncogenic signals and induces metabolic programs favoring cell growth and proliferation as well as tumor progression. Recently, cholesterol has been identified as a natural ERRα ligand using a combined biochemical strategy. This new finding highlighted some important physiological aspects related to the use of cholesterol-lowering drugs such as statins and bisphosphonates. Even more meaningful is the link between increased cholesterol levels and certain cancer phenotypes characterized by an overexpressed ERRα such as mammary, prostatic, and colorectal cancers, where the metabolic adaptation affects many cancer processes. Moreover, high-energy demanding cancer-related processes are strictly related to the cross-talk between tumor cells and some key players of tumor microenvironment, such as tumor-associated macrophage that fuels cancer progression. Some evidence suggests that high cholesterol content and ERRα activity favor the inflammatory environment by the production of different cytokines. In this review, starting from the most recent observations on the physiological role of the new signaling activated by the natural ligand of ERRα, we propose a new hypothesis on the suitability to control cholesterol levels as a chance in modulating ERRα activity in those tumors in which its expression and activity are increased

Statins reduce intratumor cholesterol affecting adrenocortical cancer growth

Mitotane causes hypercholesterolemia in ACC patients. We suppose that cholesterol increases within the tumor and can be used to activate proliferative pathways. In this study, we used statins to decrease intratumor cholesterol and investigated the effects on ACC growth related to ER\u3b1 action at the nuclear and mitochondrial levels. We first used microarray to investigate mitotane effect on genes involved in cholesterol homeostasis and evaluated their relationship with patients' survival in ACC TCGA. We then blocked cholesterol synthesis with simvastatin and determined the effects on H295R cell proliferation, estradiol production and ER\u3b1 activity in vitro and in xenograft tumors. We found that mitotane increases intratumor cholesterol content and expression of genes involved in cholesterol homeostasis, among them INSIG, whose expression affects patients' survival. Treatment of H295R cells with simvastatin to block cholesterol synthesis decreased cellular cholesterol content and this affected cell viability. Simvastatin reduced estradiol production and decreased nuclear and mitochondrial ER\u3b1 function. A mitochondrial target of ER\u3b1, the respiratory complex IV (COX IV) was reduced after simvastatin treatment, which profoundly affected mitochondrial respiration activating apoptosis. In vivo experiments confirmed the ability of simvastatin to reduce tumor volume and weight of grafted H295R cells, intratumor cholesterol content, Ki-67 and ER\u3b1, COX IV expression and activity and increase TUNEL positive cells. Collectively these data demonstrate that a reduction in intratumor cholesterol content prevents estradiol production, inhibits mitochondrial respiratory chain inducing apoptosis in ACC cells. Inhibition of mitochondrial respiration by simvastatin represents a novel strategy to counteract ACC growth

Inhibition of estrogen-dependent cyclin D1 expression by androgen receptor in MCF-7 breast cancer cell

Dottorato di Ricerca in Dottorato di Ricerca in Biochimica Cellulare ed Attività dei Farmaci in Oncologia, XIX Ciclo, a.a. 2006-2007Università della Calabri

Chenodeoxycholic acid (CDCA) through TGR5-dependent CREB-signaling activation enhances Cyclin D1 expression and promotes human endometrial cancer cell proliferation

Dottorato di Ricerca in Dottorato di Ricerca in Biochimica Cellulare ed Attività dei Farmaci in Oncologia, XXIV Ciclo, a.a. 2010-2011Increasing epidemiologic data in humans as well as many in vitro investigative reports suggest that overweight and obesity are important risk factors for type-I EC which is the most common malignancy in women and accounts for 80% of all ECs. The strongest support for mechanisms to link obesity and cancer risk involves the metabolic and endocrine effects of obesity and the alterations that they induce in the production of peptide and steroid hormones. One way in which fat might exert its effect is stimulation of bile acids (BAs) synthesis and secretion. Bile acids (BAs) are amphipathic detergents that are synthesized in the liver and stored in the gallbladder. An important physiological role of BAs is to facilitate the uptake of lipids together with the fat-soluble vitamins A, D, E and K from the intestine. BAs facilitate these absorptive processes through their detergent properties, which allow the emulsification of lipids. Moreover, BAs have evolved over the past few years from being considered as simple lipid solubilizers to complex metabolic integrators. Beyond the orchestration of bile acids, lipid and glucose metabolism by the nuclear receptor farnesoid X receptor (FXR), BAs also act as signaling molecules through the non-genomic pathway activated by a BAdedicated G protein-coupled receptor (GPCR) TGR5 (also known as BG37 or MBAR). Despite the efficient enterohepatic recirculation of bile acids, a small amount of them can spill over into the systemic circulation particularly during high fat diet. Since in the obese women a strong correlation with endometrial cancer does exist, we investigated the biological effects of different concentrations of the primary bile acid CDCA in a human endometrial type-I cancer cell line, Ishikawa. Ishikawa cell proliferation was determined by [3H]-thymidine incorporation assay after 72 hours of treatment with different concentrations of CDCA. The effects of CDCA on the expression of the cell cycle regulatory proteins were evaluated by RT-PCR and Western blotting assays. Transient transfection method and mutagenesis studies were performed to functionally characterize the Cyclin D1 promoter while ChIP assay was to highlight the direct involvement of the ciselements in CDCA-dependent Cyclin D1 up-regulation. In addition, the effects of impaired expression and function of the proteins involved in CDCA activated signaling were assessed by using small interfering RNAs (siRNAs) technology. Our results indicate that low concentrations (< 30μM) of CDCA were able to stimulate Ishikawa cell growth as evidenced by [3H]Thymidine incorporation and cell cycle analysis by inducing a significant increase in Cyclin D1(CD1) protein and mRNA expression. In contrast, according to previous findings, high doses (> 50μ) of CDCA showed cytotoxic effects concomitantly with an increase of CDK inhibitor p21WAF1/CIP1 expression through a p53-indipendent pathway. Moreover, mutagenesis studies and ChIP analysis revealed that the CDCA-induced CD1 expression requires a cyclic AMP-responsive element (CRE) binding protein motif within the CD1 proximal promoter. Silencing of a cell surface bile acid sensor TGR5 and/or CREB gene expression by RNA interference reversed the CDCA-dependent induction of CD1 expression and proliferation in Ishikawa cells. In conclusion, extrahepatic spillover of BAs following high fat diet particularly in overweight and obese women, could be involved in the onset and/or maintenance of endometrial cancer by stimulation of TGR5 that activates ERK signaling that in turn induces the recruitment of the transcription factor CREB to the Cyclin D1 gene promoter enhancing cell proliferationUniversità della Calabri